Daniel Brungs

机构：University of Wollongong, Wollongong Hospital, Illawarra Shoalhaven Local Health District · ORCID：0000-0002-8154-6966

发表论文 96 篇 · 总被引 1713 次 · h-index 21

代表论文

• Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study (2024 · Journal of Clinical Oncology · 被引 214)
• Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma (2025 · New England Journal of Medicine · 被引 68)
• Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial (2025 · The Lancet · 被引 62)
• OA08.03 Datopotamab Deruxtecan Vs Docetaxel in Patients with Non-Small Cell Lung Cancer: Final Overall Survival from TROPION-Lung01 (2024 · Journal of Thoracic Oncology · 被引 5)
• Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of ≥2 years (2025 · Journal of the American Academy of Dermatology · 被引 4)
• Phase 3 trial of adjuvant cemiplimab (cemi) versus placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC). (2025 · Journal of Clinical Oncology · 被引 4)